Bionano Genomics Announces Major Updates to Its Solve™ and Access™ Data Solutions Adding Significant New Variant Detection, Analysis and Reporting Capabilities for Optical Genome Mapping on the Saphyr® System
03 November 2021 - 11:00PM
Bionano Genomics, Inc. (BNGO), developer of the Saphyr® system
that uses optical genome mapping (OGM) for the detection and
analysis of structural variants (SVs), today announced the release
of Bionano Solve™ version 3.7 and Bionano Access™ version 1.7 as
available data solution upgrades for Saphyr systems installed in
laboratories worldwide. Included in these updates are significant
improvements in variant detection, as well as workflow
simplifications and other benefits designed to support clinical
research in inherited genetic diseases and cancer. All new Saphyr
system installations will include these versions.
New OGM capabilities include the means to detect more
clinically-relevant variants such as absence of heterozygosity
(AOH) and allelic imbalance, the first two classes of variations
that are typically considered as sequence rather than structural
variants. The updates will also enable users to visualize
chromosomal AOH across the genome similarly to single nucleotide
polymorphism (SNP) microarrays. In addition, OGM users will have
the ability to detect uniparental isodisomy UPD, regions identical
by decent (IBD), triploidy and improved characterization of mosaic
SVs through variant allele fraction (VAF) plots.
Also as part of this release, the family of
EnFocus™ targeted analysis panels now includes one for Fragile
X, a repeast expansion disorder. EnFocus Fragile X is an analytical
routine that automates the process of sizing the Fragile X repeat
with high accuracy, precision and sensitivity, thereby reducing the
time to results for researchers.
Bionano has streamlined the analytical workflow tied to OGM
through this software release. The new workflow enables all SVs
detected by Solve and analyzed with Access to be named and
classified using standard terminology according to the 2020
International System for Human Cytogenomic Nomenclature (ISCN).
This new classification is expected to simplify the reporting and
interpretation of research findings, making it easier to compare
information across other databases.
“These ongoing improvements in the performance of our software
for detecting SVs, as well as the tools for interpreting and
reporting calls, continue to impress me,” said Erik Holmlin, PhD,
CEO of Bionano Genomics. “We believe this update is significant
because of the AOH and allelic imbalance functionality we are
introducing. With our acquisition of BioDiscovery now complete, we
can begin work to integrate our variant detection technology with
NxClinical’s visualization, interpretation and reporting
capabilities to offer a potentially outstanding window through
which researchers can obtain the data to drive their science.”
About Bionano Genomics
Bionano is a provider of genome analysis solutions that can
enable researchers and clinicians to reveal answers to challenging
questions in biology and medicine. The Company’s mission is to
transform the way the world sees the genome through optical genome
mapping (OGM) solutions, diagnostic services and software. The
Company offers OGM solutions for applications across basic,
translational and clinical research. Through its Lineagen business,
the Company also provides diagnostic testing for patients with
clinical presentations consistent with autism spectrum disorder and
other neurodevelopmental disabilities. Through its BioDiscovery
business, the Company also offers an industry-leading,
platform-agnostic software solution, which integrates
next-generation sequencing and microarray data designed to provide
analysis, visualization, interpretation and reporting of copy
number variants, single-nucleotide variants and absence of
heterozygosity across the genome in one consolidated view. For more
information, visit www.bionanogenomics.com, www.lineagen.com or
www.biodiscovery.com
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,”
“estimate,” “intend” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) convey uncertainty of future events or outcomes and
are intended to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: the expected benefits
and significance of the Solve and Access upgrades; and our work to
integrate our variant detection technology with NxClinical’s
visualization, interpretation and reporting capabilities, including
the products developed through such integration. Each of these
forward-looking statements involves risks and uncertainties. Actual
results or developments may differ materially from those projected
or implied in these forward-looking statements. Factors that may
cause such a difference include the risks and uncertainties
associated with: our ability to integrate BioDiscovery’s
capabilities with our technology; issues related to the release of
new products; the impact of the COVID-19 pandemic on our business
and the global economy; general market conditions; changes in the
competitive landscape and the introduction of competitive products;
our hiring efforts may not achieve the anticipated results; changes
in our strategic and commercial plans; our ability to obtain
sufficient financing to fund our strategic plans and
commercialization efforts; the ability of medical and research
institutions to obtain funding to support adoption or continued use
of our technologies; the loss of key members of management and our
commercial team; and the risks and uncertainties associated
with our business and financial condition in general,
including the risks and uncertainties described in our filings with
the Securities and Exchange Commission, including, without
limitation, our Annual Report on Form 10-K for the year ended
December 31, 2020 and in other filings subsequently made by us with
the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. We do not undertake any
obligation to publicly update any forward-looking statements,
whether as a result of the receipt of new information, the
occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics,
Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1 (858)
366-3243amy@juniper-point.com
Media Relations:Michael SullivanSeismic+1 (503)
799-7520michael@teamseismic.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Apr 2024 to May 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From May 2023 to May 2024